Beigene Ltd(BGNE)stock report

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company’s main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Finance:
Current cash:1232M, Latest quarter loss:308M,去年亏损674M,可以烧1~2年。

EPS and Sales:
https://finance.yahoo.com/quote/BGNE/financials?p=BGNE

Date EPS % last year % last quarter
2018.12.31 -0.93 -447.06% -37.63%
 2019.3.31 -2.81 -38.42% -202.15%
2019.6.30 -0.33 13.16% 88.26%
 2019.9.30 -0.72 -24.14% -118.18%

 

Date Sales % last year % last quarter
2018.12.31 198M -16.85% 29.29%
 2019.3.31 77.83M 139.16% -60.69%
2019.6.30 321M 276.32% 312.44%
 2019.9.30 371M 166.08% 15.58%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=BGNE&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/BGNE/institutional-ownership/

Analyst Ratings:
https://www.tipranks.com/stocks/BNGE/price-targe

Leave a Reply